Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4 Pt 2
|
pubmed:dateCreated |
1989-5-18
|
pubmed:abstractText |
Quinapril (Q) and quinaprilat (QT) pharmacokinetics are dose proportional following single oral 2.5- to 80-mg Q doses. Q absorption and hydrolysis to QT is rapid with peak Q and QT concentrations occurring one and two hours postdose, respectively. Peak plasma QT concentrations were approximately fourfold higher than those of Q (923 vs 207 ng/mL following 40-mg Q). Dose-proportional QT area under the curve and dose-independent percent of dose excreted in urine as QT demonstrate that the extent of Q conversion to QT is constant over the dose range studied. Q and QT were eliminated from plasma with apparent half-lives of 0.8 and 1.9 hours and apparent plasma clearances of 1,850 and 220 mL/min, respectively, over the 2.5- to 80-mg dose range. Following oral 14C-Q, 61% and 37% of radiolabel was recovered in urine and feces, respectively. Q plus QT accounted for 46% of radioactivity circulating in plasma and 56% of that excreted in urine. Metabolism to compounds other than QT is not extensive. Two diketopiperazine metabolites of Q have been identified in plasma and urine, with approximately 6% of an administered dose excreted in urine as each of these metabolites. Peak plasma concentrations of these metabolites are similar to that of Q, and each is eliminated rapidly with a half-life of approximately one hour. Urinary excretion profiles indicate the presence of other minor metabolites. In summary, the absorption of Q and conversion to QT is rapid and dose-proportional, subsequent clearance of both Q and QT is independent of dose, and metabolism to compounds other than QT is not extensive.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin-Converting Enzyme...,
http://linkedlifedata.com/resource/pubmed/chemical/Isoquinolines,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrahydroisoquinolines,
http://linkedlifedata.com/resource/pubmed/chemical/quinapril,
http://linkedlifedata.com/resource/pubmed/chemical/quinaprilat
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0003-3197
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
40
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
351-9
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:2705643-Absorption,
pubmed-meshheading:2705643-Adult,
pubmed-meshheading:2705643-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:2705643-Half-Life,
pubmed-meshheading:2705643-Humans,
pubmed-meshheading:2705643-Isoquinolines,
pubmed-meshheading:2705643-Male,
pubmed-meshheading:2705643-Random Allocation,
pubmed-meshheading:2705643-Tetrahydroisoquinolines
|
pubmed:year |
1989
|
pubmed:articleTitle |
The clinical pharmacokinetics of quinapril.
|
pubmed:affiliation |
Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Michigan.
|
pubmed:publicationType |
Journal Article
|